Form 8-K aTYR PHARMA INC For: Jun 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
aTyr Pharma (LIFE) Reports Q1 Loss of $9.39/Share
June 18, 2015 4:25 PM EDTaTyr Pharma (NASDAQ: LIFE) reported Q1 EPS of ($9.39), versus ($7.87) reported last year.
The Company successfully completed its initial public offering following the end of the quarter on May 12, 2015, with estimated net proceeds of $76.9 million. Total cash and investments are expected to be approximately $145 million as of June 30, 2015.
Proceeds raised during the first half of 2015 will be used to fund operations, including the ongoing Phase 1b/2 clinical trial of Resolaris, a first-in-class protein therapeutic in adult patients... More
